Company detailsCode: NovoCompany name: Novo NordiskCompany country: DenmarkNumber of employees: 41571Sector: C - ManufacturingSector detail: C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparationsSub-sectors: C21.2.0 - Manufacture of pharmaceutical preparations Reshoring detailsReshoring announcement date: 22/12/2016Starting implementation date: December, 2016End of Implementation : January, 2017Reshored to: DenmarkLocation of affected unit(s): CopenhagenLocation code: DK01Reshored business function: AdministrationPartial or Total reshoring: TotalReshoring governance mode: In house (in own facilities)Estimated job gains: 55Reasons for reshoring: Firm's global reorganizationCase narrative: Novo Nordisk is a Danish pharmaceutical company. The firm has decided to move its European headquarters from Zürich (Switzerland) to the homeland, Copenhagen (Denmark). Through the relocation 55 positions are created in Denmark. Among these, 20 employees will be relocated to Switzerland, having agreed to move to Denmark. This means that the firm hired 35 new employees. The new headquarters have been opened on 2 January 2017. Sources: Berlingske, 22/12/2016 Offshoring detailsOffshoring location: Switzerland